I-ACT for Children: helping close the gap in drug approval for adults and children

Max J Coppes^{1

2

3}, Cindy Jackson⁴, Edward M Connor^{4

5}

Affiliations

¹ Departments of Pediatrics and Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA. mcoppes@renown.org.
² Renown Children's Hospital, Reno, NV, USA. mcoppes@renown.org.
³ I-ACT for Children, Rockville, MD, USA. mcoppes@renown.org.
⁴ I-ACT for Children, Rockville, MD, USA.
⁵ Departments of Pediatrics, Microbiology, Immunology, and Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Max J Coppes et al. Pediatr Res. 2023 Jun.

. 2023 Jun;93(7):1786-1787.

doi: 10.1038/s41390-022-02349-5. Epub 2022 Oct 21.

Max J Coppes^{1

2

3}, Cindy Jackson⁴, Edward M Connor^{4

5}

¹ Departments of Pediatrics and Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA. mcoppes@renown.org.
² Renown Children's Hospital, Reno, NV, USA. mcoppes@renown.org.
³ I-ACT for Children, Rockville, MD, USA. mcoppes@renown.org.
⁴ I-ACT for Children, Rockville, MD, USA.
⁵ Departments of Pediatrics, Microbiology, Immunology, and Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

No abstract available

Conflict of interest statement

One of the authors, C.J. is an employee of I-ACT for Children. Both other authors are non-compensated Board members of I-ACT for Children.

1. Allen HC, et al. Off-label medication use in children, more common than we think: a systematic review of the literature. J. Okla. State Med. Assoc. 2018;111:776–783. - PMC - PubMed
1. Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914–1915. doi: 10.1001/jama.2012.3435. - DOI - PubMed
1. de Lima Costa HTM, Costa TX, Martins RR, Oliveira AG. Use of off-label and unlicensed medicines in neonatal intensive care. PLoS ONE. 2018;13:e0204427. doi: 10.1371/journal.pone.0204427. - DOI - PMC - PubMed
1. RACE Act poised to advance pediatric cancer research. Cancer Discov. 10: 1434 (2020). - PubMed
1. Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact of the priority review voucher program on drug development for rare pediatric diseases. Health Aff. 2019;38:313–319. doi: 10.1377/hlthaff.2018.05330. - DOI - PubMed